Chongqing Pharscin Pharmaceutical (002907) Stock Overview
Chongqing Pharscin Pharmaceutical Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
002907 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Chongqing Pharscin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.32 |
| 52 Week High | CN¥22.69 |
| 52 Week Low | CN¥11.42 |
| Beta | -0.30 |
| 1 Month Change | -4.00% |
| 3 Month Change | -2.57% |
| 1 Year Change | 16.99% |
| 3 Year Change | 32.47% |
| 5 Year Change | -2.16% |
| Change since IPO | 150.31% |
Recent News & Updates
Recent updates
Pinning Down Chongqing Pharscin Pharmaceutical Co., Ltd.'s (SZSE:002907) P/S Is Difficult Right Now
Jan 13
Why Chongqing Pharscin Pharmaceutical's (SZSE:002907) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 04Chongqing Pharscin Pharmaceutical Co., Ltd.'s (SZSE:002907) Popularity With Investors Is Under Threat From Overpricing
Oct 03Chongqing Pharscin Pharmaceutical Co., Ltd.'s (SZSE:002907) 30% Price Boost Is Out Of Tune With Revenues
Mar 06Shareholder Returns
| 002907 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.2% | 0.7% | 1.8% |
| 1Y | 17.0% | 17.6% | 24.1% |
Return vs Industry: 002907 matched the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 002907 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 002907 volatility | |
|---|---|
| 002907 Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 002907 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002907's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,384 | Xiaoying Liu | www.pharscin.com |
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, soft capsules, powder injections, freeze-dried powders, injections, chemical raw materials, and small volume injections. It provides its products for the treatment of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases.
Chongqing Pharscin Pharmaceutical Co., Ltd. Fundamentals Summary
| 002907 fundamental statistics | |
|---|---|
| Market cap | CN¥6.82b |
| Earnings (TTM) | CN¥83.47m |
| Revenue (TTM) | CN¥798.88m |
Is 002907 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002907 income statement (TTM) | |
|---|---|
| Revenue | CN¥798.88m |
| Cost of Revenue | CN¥339.13m |
| Gross Profit | CN¥459.75m |
| Other Expenses | CN¥376.28m |
| Earnings | CN¥83.47m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 57.55% |
| Net Profit Margin | 10.45% |
| Debt/Equity Ratio | 0% |
How did 002907 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 00:14 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chongqing Pharscin Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.